News: Johnson & Johnson (JNJ)

JNJ on New York Consolidated

103.22USD
27 Aug 2014
Price Change (% chg)

$-0.22 (-0.21%)
Prev Close
$103.44
Open
$103.60
Day's High
$103.72
Day's Low
$102.91
Volume
4,786,441
Avg. Vol
6,155,019
52-wk High
$106.74
52-wk Low
$85.50

Search Stocks
Select another date:

Mon, Aug 4 2014

Healthcare: A remedy for long-term investors

CHICAGO - (The opinions expressed here are those of the author, a columnist for Reuters.)

COLUMN-Healthcare: A remedy for long-term investors

(The opinions expressed here are those of the author, a columnist for Reuters.)

J&J seeks return of device seen as possibly raising cancer risk

- Johnson & Johnson said on Wednesday it plans to ask doctors to return its power morcellators, a controversial surgical device that may inadvertently spread cancer in women being treated for uterine growths called fibroids.

J&J seeks return of device seen as possibly raising cancer risk

July 30 - Johnson & Johnson said on Wednesday it plans to ask doctors to return its power morcellators, a controversial surgical device that may inadvertently spread cancer in women being treated for uterine growths called fibroids.

Europe backs new leukemia drugs from J&J and Gilead

LONDON - Two new leukemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.

Europe backs new leukaemia drugs from J&J and Gilead

LONDON, July 25 - Two new leukaemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.

BRIEF-EU medicines agency backs new drugs from Novo Nordisk, J&J, Gilead

July 25 - The European Medicines Agency: * EU medicines agency says recommends Novo Nordisk diabetes

US STOCKS-Wall St dips after Yellen comments on valuations

* New York manufacturing hits highest level since April 2010

J&J beats forecasts, helped by new hepatitis C drug

- Johnson & Johnson reported higher-than-expected quarterly results on sizzling sales of its new Olysio treatment for hepatitis C, but company officials cautioned the pill will lose steam later this year as newer rivals come to market.

UPDATE 3-J&J beats forecasts, helped by new hepatitis C drug

July 15 - Johnson & Johnson reported higher-than-expected quarterly results on sizzling sales of its new Olysio treatment for hepatitis C, but company officials cautioned the pill will lose steam later this year as newer rivals come to market.

Select another date:
Search Stocks